Moderna and Merck said Wednesday that an experimental mRNA vaccine combined with Keytruda showed signs of preventing high-risk melanoma recurrence [1, 2].
This development represents a potential shift in oncology by using personalized mRNA technology to prime the immune system against specific cancer markers. If approved, the treatment could provide a new therapeutic option for patients facing a high probability of cancer return.
The late-stage trial focused on patients with high-risk disease to determine if the combination therapy could stop the cancer from returning or spreading [1, 2]. According to some reports, the vaccine cut the risk of melanoma recurrence by nearly 50% [3]. Other reports said the treatment extended the time before the cancer returned, though they did not provide a specific percentage [1].
The vaccine works in tandem with Keytruda, an immunotherapy drug produced by Merck [1]. The mRNA component is designed to target proteins specific to the patient's tumor, while the immunotherapy helps the immune system recognize and attack those cells more effectively [1, 2].
Market reaction to the news was immediate. Moderna shares rose approximately 60% in pre-market trading following the announcement [2].
Researchers are continuing to analyze the trial data to determine the long-term efficacy of the treatment. The companies aim to reduce the risk of melanoma returning in patients who have already undergone primary treatment for the disease [1, 2].
“The vaccine cut the risk of melanoma recurrence by nearly 50%”
The success of this trial suggests that the mRNA platform, which gained global prominence during the COVID-19 pandemic, is viable for personalized cancer treatment. By combining a tailored vaccine with an existing immunotherapy like Keytruda, clinicians may be able to create a 'one-two punch' that prevents relapse in high-risk patients, potentially moving cancer care toward a more preventative, personalized model.
